New York State Teachers Retirement System Makes New $1.45 Million Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

New York State Teachers Retirement System acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, HoldingsChannel.com reports. The fund acquired 5,283 shares of the biopharmaceutical company’s stock, valued at approximately $1,453,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its holdings in Alnylam Pharmaceuticals by 37.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 36,340 shares of the biopharmaceutical company’s stock valued at $9,995,000 after buying an additional 9,831 shares during the last quarter. Traynor Capital Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $1,994,000. Smith Group Asset Management LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $770,000. Pallas Capital Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 61.8% during the 3rd quarter. Pallas Capital Advisors LLC now owns 3,321 shares of the biopharmaceutical company’s stock worth $975,000 after acquiring an additional 1,269 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 41.4% during the third quarter. Nisa Investment Advisors LLC now owns 11,528 shares of the biopharmaceutical company’s stock worth $3,171,000 after purchasing an additional 3,373 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on ALNY. Raymond James raised their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 4th. Barclays raised their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Finally, Scotiabank upped their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. Six research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $294.50.

Alnylam Pharmaceuticals Stock Up 1.9 %

ALNY opened at $277.43 on Friday. The business has a 50 day simple moving average of $274.17 and a 200-day simple moving average of $230.84. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The stock has a market capitalization of $35.78 billion, a P/E ratio of -105.89 and a beta of 0.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same period in the prior year, the business posted $1.15 earnings per share. The business’s revenue for the quarter was down 33.3% compared to the same quarter last year. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.